HAMBURG, Germany, October 6 /PRNewswire-FirstCall/ -- Evotec OAI AG (Frankfurt Stock Exchange: EVT, TecDAX 30) today announced that it has signed an agreement with ALTANA Pharma AG to advance the discovery on one of their kinase targets. Applying Evotec OAI's drug discovery engine from target to clinic the companies aim to identify and optimise novel lead compounds that interact with the target in the research programme.
In this research collaboration with ALTANA Evotec OAI will develop the kinase assay, screen it against Evotec OAI's library of over 250,000 drug-like compounds using its proprietary high throughput screening technology EVOscreen(R) and characterise the hits generated. In the subsequent medicinal chemistry programme, the hits will be further optimised in terms of their potency, selectivity, ADMET and pharmacokinetic profile to identify lead compounds to advance towards the clinic.
Dr Mark Ashton, President, Drug Discovery Services at Evotec OAI, said: "We are delighted to be working with Altana on this lead identification programme. This is another example where we can bring our powerful discovery engine combined with exemplified target class expertise in the field of kinases to bear in a research programme with one of Europe's finest pharma companies."
Dr. Ulrich Thibaut, Vice President Discovery Research at ALTANA Pharma, commented: "Pharmaceutical research collaborations with competent external partners are important to supplement in-house drug discovery knowledge and experience. The relationship between Altana and Evotec OAI has developed since 2001. By setting up highly innovative assay systems in a remarkably short time frame Evotec OAI has already proven to us to be an excellent drug discovery partner and we are looking forward to expand our partnership."
About Evotec OAI AG
Evotec OAI is a leader in the discovery and development of the next generation of novel small molecule based drugs through both contract research partnerships and discovery programmes for out-licensing. The company provides innovative solutions from Target to Clinic through an unmatched range of integrated capabilities ranging from assay development and screening through to medicinal chemistry and drug manufacturing. As a result, Evotec OAI has established itself as the partner of choice for pharmaceutical and biotechnology companies worldwide. With over 600 people located in Hamburg, Germany and near Oxford, UK, Evotec OAI is committed to generate value to its partners, shareholders and employees through a sustainable strategy that balances short-term and long-term business opportunities.
About ALTANA Pharma AG
ALTANA Pharma AG is the pharmaceutical division of ALTANA AG, headquartered in Konstanz, Germany. The international pharmaceutical group employs more than 8,000 people in 30 subsidiaries and is present in markets in Europe, North and South America, Asia, South Africa and Australia. In 2003, the company achieved sales of about EUR2 billion, up 6% from 2002.
ALTANA Pharma concentrates on innovative pharmaceutical products in therapeutics, imaging (contrast media) and OTC medication. Therapeutics, the most important business area, is based on prescription drugs for gastrointestinal and respiratory diseases. Research focuses on gastroenterology, respiratory/inflammation and oncology.
Evotec OAI AG